Literature DB >> 16389655

In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.

Jeffrey R J Richardson1, Jan Abel Olsen.   

Abstract

Whether to include or exclude consumption costs and costs of unrelated illnesses in economic evaluation is not a technical issue which may be answered by reference to individuals alone and the consistency of the treatment of individual costs and benefits. In the context of a publicly funded health service the relevant costs and benefits may differ from those normally included in evaluation studies. Specifically, the social welfare function is likely to exclude benefits which would result in preferential care for wealthier members of society. But this conclusion must be established by analysis of social, not individual, values. Copyright 2005 John Wiley & Sons, Ltd.

Mesh:

Year:  2006        PMID: 16389655     DOI: 10.1002/hec.1066

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  5 in total

Review 1.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al.

Authors:  Pieter van Baal; David Meltzer; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

3.  Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs.

Authors:  Daniel T Grima; Lisa M Bernard; Elizabeth S Dunn; Philip A McFarlane; David C Mendelssohn
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

4.  Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

Authors:  Linda M de Vries; Pieter H M van Baal; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

5.  Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary.

Authors:  Erik Nord; Christoffer Lamøy
Journal:  Pharmacoecon Open       Date:  2018-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.